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Abstract
Purpose The analysis of longitudinal health-related
quality of life measures (HRQOL) can be seriously ham-
pered due to informative drop-out. Random effects models
assume Missing At Random and do not take into account
informative drop-out. We therefore aim to correct the bias
due to informative drop-out.
Methods Analyses of data from a trial comparing stan-
dard-dose and high-dose chemotherapy for patients with
breast cancer with respect to long-term impact on HRQOL
will serve as illustration. The subscale Physical Function
(PF) of the SF36 will be used. A pattern mixture approach
is proposed to account for informative drop-out. Patterns
are deﬁned based on events related to HRQOL, such as
death and relapse. The results of this pattern mixture
approach are compared to the results of the commonly used
random effects model.
Results The ﬁndings of the pattern mixture approach are
well interpretable, and different courses over time in
different patterns are distinguished. In terms of estimated
differences between standard dose and high dose, the
results of both approaches are slightly different, but have
no consequences for the clinical evaluation of both doses.
Conclusion Under the assumption that drop-out is at
random within the patterns, the pattern mixture approach
adjusts the estimates to a certain degree. This approach
accounts in a relatively simple way for informative drop-
out.
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Introduction
Treatment for cancer can affect patient quality of life [1, 2].
Therefore, health-related quality of life (HRQOL) mea-
sures are frequently included in randomized clinical trials
in oncology. The interpretation of results for HRQOL
within these randomized trials can be seriously hampered
by drop-out due to relapse and death, especially because
these events do affect HRQOL.
In longitudinal studies, observations of patients can be
missed at a certain time point because they miss visits or do
not ﬁll in certain questionnaires, although they still partici-
pate in the study. Consequently, these patients have
responses on a subset of outcome measures at different time
points. Alternatively patients can drop-out, i.e., not partici-
patinginthestudyafteracertainmoment.Thesepatientsare
lost to follow-up, and no information is available. In our
study, we deﬁne drop-out as not ﬁlling in the HRQOL
questionnaire after a certain time point, while there could be
information about the survival status after that time.
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DOI 10.1007/s11136-009-9564-1There exist different reasons for drop-out. Except for
drop-out caused by relapse or death, drop-out occurs due to
censoring, administrative, or person-related reasons. The
reasons for drop-out are often referred to as the drop-out
mechanism [3]. It is important to distinguish different types
of drop-out mechanisms, because each drop-out mechanism
requires different analyses to get valid results. A common
classiﬁcation of drop-out mechanisms has been introduced
by Rubin and can be summarized as follows: Missing
Completely At Random (MCAR), Missing At Random
(MAR), and Missing Not At Random (MNAR) [4].
Drop-out can be considered MCAR if the probability that
a patient drops out is independent of the observed (past)
response measurements and of current and future response
measurements. Or, to put in other words: patients drop-out
due to completely unrelated reasons. For example, when
HRQOL data are lost due to administrative failure, the drop-
out can be considered MCAR: the drop-out is unrelated to
HRQOL scores, and therefore does not depend on the
observed nor on unobserved HRQOL scores. Under the
assumption of MCAR, complete case analysis (including
only those patients with complete data) will give valid
results.
Drop-out can be considered MAR, if the probability of
drop-out depends on previously observed response mea-
sures, but not on the current and future measures. However,
given the observed response measures, drop-out is assumed
to be independent of the unobserved (current and future)
response measures. For example, when a patient drops out
because the HRQOL score is lower at earlier measure-
ments, the drop-out can be considered MAR. In this situ-
ation, one is able to predict the measurement after drop-out
based on past measurements, and random effects models
(mixed models) would provide unbiased results if the
model is correctly speciﬁed. In many situations, this drop-
out mechanism will be present in the data.
Drop-out is missing not at random (MNAR) if the prob-
ability of drop-out is also dependent on the unobserved
(current and future) response measures. In this situation, the
missing measurement itself is informative. For example,
whenapatienthasasuddendecreaseinHRQOLanddecides
nottoﬁllinthe questionnaire, the drop-outisMNAR.Inthis
situation, we can not predict the missing HRQOL of this
patient without making further (untestable) assumptions.
The reason of a sudden decrease could be the occurrence of
tumorrelapse,orthe factthat apatient isdying.So,drop-out
due to tumor relapse and death might be informative.
In trials, it is quite common to analyze longitudinal data
with random effects models. This type of models can
handle missing data and give valid results if MAR can be
assumed. In these models, the patients’ courses over time
are speciﬁed using regression equations per patient, taking
the correlation between the different measurements within
patients into account. Therefore, a random effects model
helps understanding about how individual patients change
across time [5]. However, without modeling, the drop-out
mechanism informative drop-out is not taken into account.
In the analysis of a trial, this might lead to serious bias, and
therefore to wrong conclusions about HRQOL. To under-
stand this, suppose that in a clinical trial, the experimental
arm reduces or postpones an event as tumor relapse. Sup-
pose, additionally, that the experimental arm has a larger
(negative) impact on HRQOL than the other arm. If
patients are less inclined to ﬁll in HRQOL questionnaires
after a relapse, then patients in the experimental arm are
more likely to ﬁll in the HRQOL questionnaires than
patients in the control arm. So, more patients with lower
HRQOL will remain in the experimental arm compared to
the control arm. In this case, complete case analysis will
yield biased results in favor of the standard arm, because
patients with missing observations after relapse are not
taken into account. A similar argument holds when using
last observation carried forward, since the high HRQOL
values before relapse are imputed for the missing HRQOL
values after death and relapse. It is therefore important to
model implicitly or explicitly the drop-out mechanism.
There are several approaches for the analysis of infor-
mative drop-out. They are rather complicated. Therefore,
their complexity may be the reason why these approaches
are not routinely employed in the analysis of randomized
clinical trials.
Historically, there are two different likelihood-based
approaches for analyses of informative drop-out that differ
with respect to the way the joint distribution of responses
and drop-out process is factorized (Curran et al. [6];
Michiels et al. [7]). These approaches are the pattern
mixture model approach (Hedeker and Gibbons [8], Pauler
et al. [9]) and the selection model approach (Diggle and
Kenward [10], Little [11], and Curran et al. [12]). In the
present paper, we will focus on the pattern mixture
approach, because this is a relatively simple extension of
the commonly used random effects model assuming MAR.
Another class of models is based on the joint modeling
of response measures (e.g., HRQOL) and times to events
(e.g., relapse and death). These models estimate the
HRQOL measures given that a person is in a certain state at
a certain time point. Examples are the models of Kurland
and Heagerty [13], and of Diggle et al. [14]. These models
take the ordering of event times explicitly into account and
regard drop-out as a consequence of events in the past. In
this sense, these models can be used for prediction. This is
in contrast to the pattern mixture approach where the drop-
out process is reﬂected in patterns and where these patterns
are determined retrospectively. This approach is therefore
primary appropriate for adjusting the estimates for the
missing data mechanism.
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123In this paper, we will use data of a Dutch multi-center
randomized clinical trial in patients with breast cancer as
illustration for the use of the pattern mixture approach. In
this trial, the long-term impact of two different chemother-
apy schedules (high dose vs. standard dose) on HRQOL was
compared. The results of the study with respect to the pri-
mary outcomes, relapse-free survival, and overall survival
have been publishedby Rodenhuiset al.[15,16]. Buijs et al.
[17] analyzed the HRQOL data comparing both treatment
arms assuming that patients remained disease free.
We aimed in this paper to correct the HRQOL estima-
tion for informative drop-out in order to get a valid com-
parison between schedules, taking events as death and
relapse into account. Since we expect that drop-out due to
relapse and death are the two main sources of informative
drop-out, we propose a pattern mixture approach in which
patterns are deﬁned based on the different disease states a
person can have at the end of the study period. The dif-
ferent states we use for the patterns are quality of life
related such as ‘death’, ‘alive with tumor relapse’, and
‘disease free’. We start considering the ‘usual’ random
effects model analysis assuming MAR. Then, we will
analyse the data with the pattern mixture approach with
HRQOL-related patterns. Thereafter, outcomes of both
approaches will be compared.
Methods
Dutch multi-center randomized clinical
breast cancer trial
From August 1993 to July 1999, 804 patients from 10
Dutch centers were randomized in the HRQL part of the
trial comparing two different chemotherapy schedules. The
standard chemotherapy arm consisted of ﬁve cycles of
5-ﬂuorouracil (500 mg/m
2), epirubicin (90 mg/m
2), and
cyclophosphamide (500 mg/m
2) (FEC). The high-dose
chemotherapy arm consisted of 4 identical cycles of FEC
followed by one cycle of high-dose chemotherapy com-
prising cyclophosphamide (6 g/m
2), thiotepa (480 mg/m
2),
and carboplatin (1600 mg/m
2) administered over 4 days
followed by peripheral blood progenitor cell reinfusion on
day 7. There were 885 patients randomized; 804 of them
participated in the HRQOL part of the trial of which 405
patients were randomly assigned to the standard therapy
and 399 patients to the experimental (high dose) therapy.
The main study was a survival study. The primary out-
comes were the overall survival and the disease-free sur-
vival. Secondary outcome measures were health-related
quality of life measures. The Medical Ethical Committees
of all participating centers approved the study. All patients
gave informed consent before study entry.
Subgroup of patients
At the time of the analysis in 2003, there appeared to be no
signiﬁcant differences following intention to treat analyses
with respect to overall and disease-free survival (Rode-
nhuis et al. [15]). However, a subgroup of patients with
normal HER2 expression did beneﬁt of high-dose chemo-
therapy as far as disease free (P = 0.002) and overall
survival (P = 0.02) were concerned (Rodenhuis et al.
[16]). In this paper, we focus therefore on this subgroup.
Only patients participating in the HRQOL part of the trial
are considered, of which 273 patients were randomized to
standard dose and 288 to high-dose chemotherapy.
Quality of life assessment
The pattern mixture model is illustrated for one of the
subscales of the SF-36 namely the physical functioning
(PF) subscale, consisting of items which indicate the ability
to perform physical activities as walking, carrying shop-
ping, and climbing stairs. The scores range from 0 to 100,
with higher scores representing higher level of functioning.
The choice of this subscale was mainly based on illustra-
tive reasons: preliminary analyses on this subscale dem-
onstrated signiﬁcant and relative large differences in favor
of the standard arm. Other subscales demonstrated smaller
(and/or not signiﬁcant) differences.
Thequestionnairesweresentbymailbeforerandomization
(baseline), after chemotherapy (about 3 months), after radio-
therapy (about 6 months), and thereafter every 6 months.
Due to the variation in entry date, not all patients could
be studied for the maximum period of 5 years and 12
measurements points. Each patient had a study period
follow-up of at least 3 years and eight measurement points.
We deﬁned patients who were alive but did not have the
maximum study period follow-up as censored.
Statistical analysis
The analyses were performed with SPSS (version 16),
MLWin (version 2.02), and R (version 2.6.2).
Descriptive
Analyses were based on intention to treat. A cross-sectional
comparison of PF between the two doses was performed at
each measurement point, presenting the observed mean and
standard error per measurement point. In this analysis,
differences in PF per time point between both doses were
based on different sets of patients. Visual inspection of the
course of the means over time gave suggestions for mod-
eling the course over time in the random effect model and
pattern mixture model.
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A large part of drop-out was due to death and censoring
(e.g., patients who did not have the maximum study period
follow-up). Patients able to ﬁll in the questionnaires at a
certain time point (the patients at risk) are the patients
being alive and being not censored at that time point.
Percentages of patients with observed HRQOL measures
(i.e., responding patients) are based on these patients at
risk, and are called response rates. They were calculated for
each time point and for each treatment.
A distinction in drop-out due to relapse and due to death
must be made. In the case of relapse, we can assume that
PF exists and is affected by a relapse, but that it is not
measured. The deﬁnition of PF after death is not directly
obvious. Therefore, three patterns were deﬁned: A pattern
consisting of patients who died during the study period
(deceased patients), a pattern with patients with relapse
who were alive at the end of the study period, and a pattern
with patients who remained disease free. A cross-sectional
comparison of the PF assessments of these patterns was
performed to analyze descriptively whether the course over
time was different for the patterns or not, and whether both
doses had different responses over time per pattern.
Random effects model (assuming MAR)
A random effects model was ﬁtted on the data with ‘course
over time’, ‘treatment’ and ‘interaction course over time by
treatment’ as ﬁxed explanatory variables for the PF
assuming MAR. In the following, this is called the ‘‘ﬁnal
model’’. Since we assumed that each patient had her own
course over time, time effects were also considered to be
random. The ‘course over time’ was speciﬁed based on the
ﬁndings of the visual inspection of the descriptive analysis.
P-values smaller than 5% were considered to be signiﬁcant.
We started with ﬁtting the empty model (Snijders and
Bosker) [18], using maximum likelihood. This was a model
without explanatory variables; only a ﬁxed intercept was
included (parameter for the overall mean) with two random
effects. This model estimated the overall mean PF of all
patients and time points and estimates the variability of the
PF within patients and between patients. Then, we ﬁtted the
timemodelusingmaximumlikelihood.Thismodelincluded
only the ﬁxed and random intercept and ﬁxed and random
time effects. This model estimated the mean PF of all
patients over time. The difference in deviance (i.e., -2 times
the value of the likelihood) between the empty model and
time model is an indication for the effect of time on PF, and
the deviances can be compared using the likelihood ratio
test. Then, the ﬁnal model ‘interaction course over time by
treatment’ was ﬁtted by maximum likelihood. This model
estimated the mean PF over time for the different treatment
arms. The performance of the ﬁnal model was evaluated by
the deviance compared to the deviance of the empty model
and to the deviance of the time model. The difference
between the ﬁnal model and the time model is an indication
of the effect of treatment over time on PF. The comparisons
of different deviances between different nested models can
be regarded as a relative for the ﬁt of the model for the data.
These modelsassumed onlyMARimplyingthatdrop-out
dependent on the missing PF score itself (for example
becauseofanunpredictabledecrease causedbyrelapse)was
not taken into account. The empty model, the time model,
and ﬁnal model are explained and speciﬁed in the appendix.
Pattern mixture approach (correction for informative
drop-out)
Inthepatternmixtureapproach,thedrop-outprocessandthe
outcome measures conditional on the drop-out pattern are
jointly modeled. The drop-out process was modeled by the
probability to belong to a speciﬁc drop-out pattern for each
dose separately, and estimated by the sample proportion.
Patterns were based on the relapse and survival state of the
patient at the end of the study period and deﬁned as before:
‘deceased’, ‘alive with relapse’, and ‘disease free’. The
outcomeconditionalonthedrop-outpatternwasmodeledby
the random effects model with additional explanatory vari-
ables indicating different follow-up patterns of patients. In
thefollowing,we callthismodel, thepatternmixture model.
We implicitly assumed that each pattern has its own missing
data process and own course over time with respect to PF.
Moreover,weassumedthatwithineachpattern,thedrop-out
is MAR. This means that conditional on being in a certain
pattern, the missing PF can be predicted based on observed
measurements of patients within this pattern. The pattern
mixture model was speciﬁed with ‘course over time’,
‘treatment’, and ‘interaction course over time by treatment’
as explanatory variables (as before), and also with the vari-
ables ‘pattern’, and all possible interactions with pattern.
This model was ﬁtted using maximum likelihood. See the
Appendixfortheexplanationandspeciﬁcationofthemodel.
Based on the difference in deviances (likelihood ratio
test), it was decided which additional explanatory terms
could be excluded from the model. This difference can be
regarded as a relative measure for the ﬁt of the model on the
data.
For each pattern, the course over time per treatment was
estimated. In order to compare both treatments for all pat-
terns together, the effects of both doses were estimated by a
weighted average over all patterns weighted by their sample
proportions. An illustration of this is given in the appendix.
With the delta-method (Bisshop et al. [19]), standard errors
of the differences between the two treatments were esti-
mated to determine the signiﬁcance of the effects.
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model and pattern mixture approach
The ﬁt of the random effects model and the random effects
part of the pattern mixture approach (i.e., the pattern
mixture model) were compared based on the difference in
deviance (likelihood ratio test). The results of the pattern
mixture approach (weighting over all patterns) in terms of
estimated differences in PF scores between both treatments
arms per time point were compared to those of the random
effects model assuming MAR.
Sensitivity analysis
Since in our data, not all patients had the maximum study
period of 5 years, the patterns ‘alive with relapse’ and
‘diseasefree’consistedofpatientsforwhichthediseasestate
after 5 years was not known yet. Therefore, we implicitly
assumed that censored patients and patients with maximum
study period could be combined within each pattern and that
this did not have consequences for the results. To check
whether the deﬁnition of patterns for all patients (with
complete and incomplete follow-up) leads to different
results than the deﬁnition of patterns for only patients with
maximum study period follow-up, we performed a sensi-
tivity analysis by also modeling the data using only patients
with complete 5-year follow-up and comparing the results.
Results
Descriptive
In Fig. 1, the observed means and standard errors of PF per
armandpermeasurementpointarepresented.Thenumberof
patients that contributes to each mean is in Table 1, in the
columnnamed‘response’.Forthehigh-dosearm,therewasa
large drop in the observed mean after 3 months (just after
chemotherapy). There was alsoa decrease inobserved mean
for the standard dose although much smaller. After
6 months, the means were increasing again in both treat-
ments.After1 year,themeansinbotharmsweresimilar,and
remainratherconstant,andtheywerehigherthanatbaseline.
Drop-out
In Table 1, the number of patients at risk (i.e., patients
being alive and being not censored), the number of
deceased, and the number of censored patients (with
incomplete study period follow-up) are presented for each
time point per chemotherapy, with also the number and
percentages of observed PF scores among all patients at
risk (response rates). For both schedules, the percentages
were comparable for each measurement point.
In Table 2, the numbers of patients for the different pat-
terns are presented. The majority of the patients belonged to
pattern 3: ‘disease free’. About 20% died within 5 years. In
Fig. 2a, the different observed courses of PF over time in
terms of observed means and standard errors are given per
pattern. There were small differences between the patterns
during the ﬁrst year, but there was an obvious difference in
the observed course over time after 1 year: the observed
meanofpatientsinthepattern‘deceasedpatients’decreased,
the mean PF of patients in the pattern ‘alive with relapse’
also decreased but less steep, and the mean PF in the pattern
relapse free was rather constant. In Fig. 2b–d, the observed
differences between mean PF over time between the doses
are presented for each pattern. During the ﬁrst year, the
observedcourseovertimewassimilarforallpatterns:alarge
drop at 3 months for the high dose, and a somewhat smaller
drop for the standard dose. However, after 1 year, the dif-
ferences between doses were not similar for the patterns. In
thepatterns‘deceased’and‘alivewithrelapse’,theobserved
courseovertimesuggeststhatpatientswhogetrecurrenceor
die within the study period beneﬁtted somewhat from the
high dose in the long run. In the ‘relapse free’ pattern, the
observed means of both doses were similar after 1 year with
a negligible difference in favor of the standard dose.
Random effects model (assuming MAR)
Based on the ﬁndings of the descriptive analysis, the course
over time was modeled by four time variables, namely
three dummy time variables t0, t1, t2 on the ﬁrst three time
points indicating the measurements at baseline, after
3 months, after 6 months, and one variable tc indicating
the time continuously after 1 year. At each measurement
point, there could be differences between both doses.
Therefore, the main effect ‘dose’ was included in the
model, together with the interaction terms of dose with the
Fig. 1 Observed mean and standard error per treatment and per time
point for all available PF measures
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estimated PF at 1 year for the standard dose. The main
effect ‘dose’ can be considered as the estimated difference
between both doses at 1 year. The sum of the main dose
effect and the interaction effect per time dummy is the
difference between doses for each time point (baseline,
after 3 months, and after 6 months). The interaction effect
with the time variable indicating the time continuously
after 1 year indicates the difference between doses in
Table 2 Number of patients per arm by survival and relapse state
Pattern Arm
Standard dose High dose Total
Deceased 68 53 121
Alive with relapse 39 28 67
Disease free 166 207 373
Total 273 288 561
Fig. 2 a Observed means and standard errors per time point per
pattern. b Observed means and standard errors per arm and per time
point for deceased patients. c Observed means and standard errors per
arm and per time point for patients alive with relapse. d Observed
means and standard errors per arm and per time point for relapse-free
patients
Table 1 The response rates per follow-up time and per treatment arm, by number at risk, number deceased, and censored patients
Follow-up time Standard-dose arm number High-dose arm number
At risk deceased censored
a Response (%)
b At risk deceased censored
a Response (%)
b
Baseline 273 0 0 251 (92) 288 0 0 271 (94)
3 months 273 0 0 244 (89) 288 0 0 257 (89)
6 months 273 0 0 248 (91) 285 3 0 250 (88)
1 year 264 9 0 242 (92) 282 6 0 251 (89)
1.5 years 251 22 0 222 (88) 279 9 0 242 (87)
2 years 248 25 0 204 (82) 268 20 0 227 (85)
2.5 years 238 35 0 195 (82) 262 26 0 213 (81)
3 years 218 41 14 187 (86) 243 30 15 205 (85)
3.5 years 183 52 38 167 (92) 216 38 34 192 (89)
4 years 158 57 58 143 (91) 187 45 56 168 (90)
4.5 years 140 63 70 128 (91) 165 49 74 143 (87)
5 years 130 68 75 102 (78) 155 53 80 127 (82)
a Number of patients alive with incomplete follow-up due to late inclusion date
b Number of patients with observed PF score among all patients at risk
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model, see Appendix). In Table 3, the ﬁtted ﬁnal model
assuming MAR is presented, together with the empty
model and the time model. The deviance of the ﬁnal ran-
dom effects model (i.e., 39,869) was much smaller than the
deviance of the empty model (i.e., 42,022) and the time
model (i.e., 40,047), indicating that the dose had a signif-
icant effect over time on the PF under the assumption of
MAR (P\0.001). In Fig. 3, the estimated mean PF scores
for both doses based on this model are presented. In
Table 4, the estimated differences between doses per time
point (at baseline, after 3 months, and after 6 months) and
the estimated difference in slope after 1 year are presented,
together with their standard errors and P-values. Just after
chemotherapy, after 3 months up to 1 year, there was a
signiﬁcant difference for PF between both arms in favor of
the standard dose. After 1 year, the slope for the high-dose
arm was nearly signiﬁcant larger (P = 0.055) than the
standard-dose arm.
Pattern mixture approach (correction for informative
drop-out)
The ﬁt of the pattern mixture model
In Table 5, the ﬁtted pattern mixture model is presented.
This model consisted of all explanatory variables of the
ﬁnal random effects model assuming MAR together with
all possible interactions with ‘pattern’. Since ‘pattern’ has
three categories, two dummy variables were deﬁned indi-
cating the pattern ‘‘relapse’’ and the pattern ‘‘relapse free’’,
respectively; the reference category is ‘deceased’. Based on
the small difference in deviance (P = 0.48), the main
effect ‘pattern’ was excluded from the model.
The estimates of the interactions between the time
variables during the ﬁrst year and the patterns are negative,
suggesting that for the standard dose, the pattern ‘‘relapse’’
and the pattern ‘‘relapse free’’ are worse in terms of PF
during the ﬁrst year than the pattern ‘‘deceased’’. However,
these estimates are not signiﬁcant.
Courses per pattern
In Fig. 4a–c, the estimated course over time for both treat-
ments is given per pattern. It is evident that the results con-
ﬁrmed the ﬁndings of the descriptive analysis: the courses
overtimewereverydifferentforthepatterns.Thedifferences
Table 3 The ﬁtted empty model, time model, and random effects
model; model estimates and standard errors
Variable Estimate (standard error)
Empty model Time model Final model
Fixed effects
Intercept 74.79 (0.62) 79.35 (0.73) 84.21 (2.32)
t0
a -3.42 (0.76) -5.41 (1.08)
t1
b -23.23 (1.19) -10.53 (1.51)
t2
c -5.72 (0.70) -3.30 (0.99)
tc
d -0.13 (0.025) -0.18 (0.04)
dose * t0
a 3.92 (1.51)
dose * t1
b -24.67 (2.11)
dose * t2
c -4.84 (1.378)
dose -3.24 (1.46)
dose * tc
d 0.10 (0.05)
Random part (variances level 2)
Intercept 176.44 (12.66) 230.43 (17.62) 227.74 (17.45)
t0
a 130.08 (19.24) 125.53 (18.95)
t1
b 540.11 (45.27) 394.17 (36.05)
t2
c 75.64 (16.02) 69.82 (15.66)
tc
d 0.18 (0.02) 0.18 (0.02)
Residual variance
260.13 (5.59) 109.98 (3.16) 109.94 (3.32)
Deviance
42,022 40,047 39,869
P-value\0.0001
a Time dummy indicating time point at baseline
b Time dummy indicating time point at 3 months (just after
chemotherapy)
c Time dummy indicating time point at 6 months
d Time variable continuously after 1 year
Fig. 3 The estimated course of PF over time per treatment based on
the ﬁnal random effects model assuming MAR
Table 4 The estimated difference between arms for the ﬁrst time
points t0 to t3 and for the slope after 1 year based on the random
effects model
Time point Estimate (standard error) P-value
t0 0.68 (1.23) 0.59
t1 -27.90 (1.97) \0.001
t2 -8.08 (1.60) \0.001
t3 -3.24 (1.46) 0.026
After t3 0.10 (0.05) 0.055
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thedescriptiveanalysis:duringtheﬁrstyear,theestimatedPF
scoresforthestandarddosewerelargerthanthoseforthehigh
dose. After 1 year, the difference in slope between the high-
dose arm and standard-dose arm for the patterns ‘deceased’
and ‘alive with relapse’ was estimated in favor of the high
dose.Forthepattern‘relapsefree’,theestimatedslopeswere
similar for both patterns, indicating that the small difference
in favor of the standard dose remained after 1 year.
All patterns together
To compare the schedules for all patterns together
(weighted over all patterns), the estimated PF for both
doses is shown in Fig. 5. In Table 6, the differences per
time point (at baseline, after 3 months, and after 6 months)
and the difference in slope after 1 year together with their
standard errors are presented. During the ﬁrst year, there
was a signiﬁcant difference in favor of the standard-dose
arm. After 1 year, the slopes differed signiﬁcantly in favor
of the high dose (P = 0.001). However, in terms of abso-
lute differences in PF between both doses, the differences
are very small (see Fig. 5).
Comparison results of both approaches
Comparing the deviance of the pattern mixture model to
the ﬁnal random effects model assuming MAR, we see that
the ﬁt was signiﬁcantly better since the difference in
deviance is large (39,626 vs. 39,869); P\0.0001). This
indicates that under the assumption of MAR within each
pattern, the pattern mixture model has a better ﬁt than the
random effects model.
Comparing the results of the random effects model
assuming MAR to the results of pattern mixture approach
(weighting over all patterns), see Tables 4 and 6, we see that
theestimateddifferencesbetweenbothdosesweresimilarfor
both approaches. However, the estimated difference in slope
Table 5 The ﬁtted pattern
mixture model; model estimates
and standard errors
a Time dummy indicating time
point at baseline
b Time dummy indicating time
point at 3 months (just after
chemotherapy)
c Time dummy indicating time
point at 6 months
d Time variable continuous
after 1 year
Variable Estimate (standard error)
Fixed effects
Intercept 81.51 (3.32)
t0
a -5.70 (1.84)
t1
b -9.74 (2.80)
t2
c -1.53 (1.96)
tc
d -1.32 (0.11)
dose * t0
a 11.54 (3.22)
dose * t1
b -14.44 (4.59)
dose * t2
c -4.40 (3.19)
dose -11.06 (2.79)
dose * tc
d 0.44 (0.17)
Interaction with patterns With relapse Relapse free
t0
a -0.80 (2.76) -0.27 (1.99)
t1
b -2.10 (4.48) -1.74 (3.24)
t2
c -5.95 (3.07) -2.32 (2.23)
tc
d 0.84 (0.13) 1.32 (0.11)
dose * t0
a -6.21 (5.16) -8.96 (3.53)
dose * t1
b -9.84 (7.38) -11.84 (5.16)
dose * t2
c 0.09 (4.96) -0.03 (3.54)
dose 8.03 (4.12) 9.04 (2.84)
dose * tc
d -0.30 (0.20) -0.43 (0.17)
Random part (variances level 2)
Intercept 225.06 (17.19)
t0
a 125.21 (18.73)
t1
b 378.90 (34.90)
t2
c 67.16 (15.29)
tc
d 0.09 (0.01)
Residual variance 108.51 (3.11)
Deviance 39,626
P-value\0.0001
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123after 1 year in the pattern mixture approach (0.21) was twice
the estimateddifference inslope ofthe randomeffects model
(0.10) and was signiﬁcant. However, in both approaches, the
absolute differences in PF after 1 year were small, as can be
concluded comparing Figs. 3, 4, and 5.
Sensitivity analysis
The results of the analysis for only patients for which the
disease state was known after 5 years (patients with maxi-
mum study period) revealed no differences compared to the
results of the analysis for all patients. Therefore, we do not
present the results for this restricted number of patients. In
our data, the consequences of deﬁning patterns based on
patientswithdifferentlengthofstudyperiodwerenegligible.
Discussion
In this paper, the pattern mixture approach as a method for
correction for informative drop-out was studied. We
illustrated this on data from a large multi-center random-
ized trial comparing the long-term impact on HRQOL of
two different doses chemotherapy for patients with breast
cancer. We only considered one dimension of the HRQOL,
namely PF. We focused on a subgroup of patients with
normal HER2 expression in their tumor for whom it was
shown that the (disease free) survival was better for the
high dose than for the standard-dose arm (Rodenhuis et al.
[16]). We compared the results of the pattern mixture
approach to the results of the commonly used random
effects model for the subscale PF.
In this particular example, the pattern mixture approach
leads to differences with respect to the estimation and
Fig. 5 The estimated course of PF over time per treatment based on
the pattern mixture model
Table 6 The estimated difference between arms for the ﬁrst time
points t0 to t3 and for the slope after 1 year based on the pattern
mixture model
Time point Estimate (standard error) P-value
t0 0.72 (1.26) 0.55
t1 -27.81 (2.01) \0.001
t2 -8.17 (1.63) \0.001
t3 -3.75 (1.47) 0.003
After t3 0.21 (0.06) 0.001
Fig. 4 a The estimated course of PF over time per treatment for pattern ‘deceased’. b The estimated course of PF over time per treatment for
pattern ‘alive with relapse’. c The estimated course of PF over time per treatment for pattern ‘disease free’
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123signiﬁcance of the difference in decline of PF measures
over time between both arms after 1 year: The estimated
difference in decline is doubled from 0.10 (P = .055) in
the random effects model to 0.21 (P = 0.001) in the pat-
tern mixture approach. However, the absolute estimated
differences in PF between both chemotherapy doses after
1 year are similar in both approaches, and therefore the
pattern mixture approach does not lead to other conclusions
than the commonly used random effects model.
In studies with a lot of missing values due to drop-out for
differentreasons,itisimportanttoexplorewhetherthedrop-
out is informative or not. It is possible that for some out-
comes the drop-out is informative, while for other outcomes
this is not. An example for this is the case where the mean
blood pressure is the main outcome in a study concerning a
clinical patient population with high blood pressure, and
where patients are repeatedly measured over time until their
blood pressure is sufﬁciently reduced. So, patients are not
measured any more (drop-out of the study) when they have
‘‘good’’ blood pressure values. In this case, the drop-out is
caused by the previous measurement, and therefore not
informative. So if one is planning a study with different sort
of outcome measures, one must consider whether the drop-
outisinformativeforeachdifferentoutcomemeasure.Inour
data, we only considered drop-out by death or relapse as the
two main sources of informative drop-out.
The crucial (and maybe the hardest) point in applying
the pattern mixture approach is the choice of the patterns.
The validity of the model estimates is determined by the
implicit assumption that within each pattern, the missing
data process is MAR. This is an untestable assumption;
testing MCAR vs. MAR is possible, but testing MAR vs.
MNAR is not (Molenberghs et al. [20]). The choice of the
patterns must be made in such a way that this assumption is
plausible. The number of patterns could be extended, based
on the exact survival time or time of relapse, for example to
account for the fact that shortly before death, the PF often
drops and the amount of missing responses increases. In
our data, we deﬁned the patterns based on HRQOL-related
events as death and relapse.
In our model, we had some censored patients, and we
used their last observed event state for grouping them into
patterns. Compared to the patients with maximum study
period, relapse-free patients who are censored could still die
or get tumor relapse within 5 years, implying that they
belong to the pattern ‘deceased’ or ‘alive with relapse’.
Analogously, patients with tumor relapse could still die
within 5 years and therefore belongs to the pattern
‘deceased’. The implication of the different length of study
period follow-up might be that the assumption of MAR
within each pattern is violated. To check this, we also
modeled the data for only patients with complete follow-up.
Comparingtheseresultswith theresultsoftheanalysisofall
patients, we found similar results with somewhat larger
standard errors. This means that for our data, there is no
large problem here on this point. But for the application on
other data with patterns based on disease states for patients
with different lengths of follow-up, one must carefully
consider the point whether the data are MAR within the
patterns, and check this by sensitivity analysis, if possible.
The patterns chosen here do have clinical relevance. It is
clinically interesting to estimate the courses over time for
relapse-free patients. This could be interesting in terms of
prediction: What is the HRQOL during the next 5 years,
assuming that patients remain disease free? However, our
model is less appropriate for the prediction for patients alive
with relapse, because the pattern is based on the state at
5 yearandtheestimatedPFmeasuresovertimearebasedon
PF measures for patients with relapse and patients who did
not yet have a relapse at that time point. The pattern
‘‘deceased’’ needs also special attention. Death is different
fromotherreasons ofmissing,where we canassume that the
quality of life exists but is not measured. If and how quality
of life after death is deﬁned is a topic of much discussion.
The random effects models used in this paper implicitly
impute missing PF scores, also after a patient has died. This
is done by extrapolating the patient’s individual trajectory
before death. One could question this approach. Therefore,
one might want to limit the analysis for patients being alive.
Pauler et al. [9] proposed to use the pattern mixture model
estimates conditional on not being in pattern ‘‘deceased’’.
Diggle et al. [14] discussed extensively the validity of dif-
ferent models accounting for informative drop-out, includ-
ing the relatively new approaches where measures (as
HRQOL) and times to events (as relapse and death) are
jointly modeled. Applying the latter models to these par-
ticularly data will be a topic for new research.
Ingeneral,itisrecommendedindatawithinformativedrop-
out to do sensitivity analysis by using different approaches.
The pattern mixture approach we propose here is rather a
simpleextensionofthecommonlyusedrandomeffectsmodels
in longitudinal data, and might therefore be routinely
employed in the analysis of randomized clinical trials.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
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Appendix
Model speciﬁcation empty model
Yij ¼ b0 þ ui þ eij;
where Yij is the HRQOL of patient i on time point j, ui the
random term indicating the between-person variability, and
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123eij the random term indicating the residual variance. The
random terms are independent and assumed to be normally
distributed with mean zero and constant variance, notated
by
ui  Nð0; r2
uÞ and eij  Nð0; r2
eÞ:
Model speciﬁcation time model
The course over time (in months after randomization) is
speciﬁed using four different time variables, namely t0, t1,
t2, and tc deﬁned as follows.
Let t0 be the dummy variable for time which equals 1
at baseline and zero afterward. Let, similarly, t1 be the
dummy variable, which equals 1 at 3 months, and zero
on other time points and t2 the dummy variable, which
equals 1 at 6 months, and zero at other time points. Let
tc be a variable equal to 0 in the ﬁrst year and equal to
time-12 thereafter. In this way, the effect of time is
assumed to be continuously increasing or decreasing after
1 year.
The time model can be speciﬁed as follows
Yij ¼ð b0 þ u0iÞ t0 þð b1 þ u1iÞ t1 þð b2 þ u2iÞ t2 þ b3
þ u3i þð bc þ uciÞ tc þ eij;
where b0, b1, b2, b3, and bc are the ﬁxed effects, and u0i,
u1i, u2i, u3i, uci the random effects.
Interpretation
b0 ? b3: HRQOL at baseline
b1 ? b3: HRQOL at 3 months (just after chemotherapy)
b2 ? b3: HRQOL at 6 months
b3: HRQOL at 1 year
bc: slope of the HRQOL course over time after 1 year
The random effects u0i, u1i, u2i, and u3i can be grouped in a
similar way, but now indicating the random variability
between patients at each time point. The random effect uci
indicates the random variability of the slope between
patients, and eij is the residual variance.
Model speciﬁcation ﬁnal model
Deﬁne
f time ðÞ ¼ ð b0 þ u0iÞ t0 þð b1 þ u1iÞ t1 þð b2 þ u2iÞ t2
þ b3 þ u3i þð bc þ uciÞ tc þ eij
indicating the time model.
The ﬁnal model is the time model plus the effect of
treatment arm and all interactions (as ﬁxed effects)
between treatment arm and time variables t0, t1, t2, and tc.
So, the ﬁnal model is speciﬁed as follows
Yij ¼ f time   dose ðÞ
¼ f time ðÞ þ bd   dose þ bd0   dose   t0 þ bd1   dose   t1
þ bd2   dose   t2 þ bdc   dose   tc;
where dose equals 1 for the high-dose arm and 0 for the
standard dose.
Notethattheinteractiontermdose t3isnotincludedinthe
model, since this would lead to over speciﬁcation of the
model. This is more evident when considering the interpre-
tationofthedifferentﬁxedeffects:eachextraparameterinthis
model reﬂects the difference in doses for each time variable.
Interpretation
bd ? bd0: difference in HRQOL between both doses at
baseline.
bd ? bd1: difference in HRQOL between both doses at
3 months.
bd ? bd2: difference in HRQOL between both doses at
6 months.
bd: difference in HRQOL between both doses at 1 year
bdc: difference in slopes between both doses after 1 year
The ﬁxed part of f(time) reﬂects the course over time for
patients in the standard dose. Filling in 1 for dose in the
ﬁxed part of f(time * dose) yields the course over time for
patients in the high dose.
Speciﬁcation of the pattern mixture model
Letpat1bethepatterndummyvariableequalto1forpatients
with relapseduringthestudyperiod,andzerootherwise.Let
pat2 be the pattern dummy variable equal to 1 for relapse-
free patients during study period, and zero otherwise.
The random effects model in the pattern mixture
approach (called the pattern mixture model) is the ﬁnal
model with additional the pattern dummy variables and all
interactions between the variables of the ﬁnal model with
these pattern dummy variables.
Let f(time * dose) be the ﬁnal model. The pattern mix-
ture model can then be speciﬁed as
Yij ¼ f time   dose ðÞ þ c1   pat1 þ c2   pat2 þ c1d   pat1   dose
þ c2d   pat2   dose þ c10   pat1   t0 þ c20   pat2   t0
þ c11   pat1   t1 þ c21   pat2   t1 þ c12   pat1   t2
þ c22   pat2   t2 þ c1c   pat1   tc þ c2c   pat2   tc
þ c1d0   pat1   dose   t0 þ c2d0   pat2   dose   t0
þ c1d1   pat1   dose   t1 þ c2d1   pat2   dose   t1
þ c1d2   pat1   dose   t2 þ c2d2   pat2   dose   t2
þ c1dc   pat1   dose   tc þ c2dc   pat2   dose   tc;
where c1 to c2dc are the ﬁxed parameters.
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The ﬁxed part of f(time * dose) indicates the course over
time for both doses for the deceased patients and can be
interpreted as in the ﬁnal model. The ﬁxed part of
f(time * dose) and additionally all variables including pat1
reﬂects the course over time for both doses for the patients
with relapse. The ﬁxed part of f(time * dose) and all
variables including pat2 reﬂects the course over time for
both doses for relapse-free patients (rel free).
So,
Yij deceased ðÞ ¼ f time   dose ðÞ
Yij relapse ðÞ ¼ f time   dose ðÞ þ c1 þ c1d   dose
þ c10   t0 þ c11   t1 þ c12   t2 þ c1c   tc
þ c1d0   dose   t0 þ c1d1   dose   t1
þ c1d2   dose   t2 þ c1dc   dose   tc
Yij rel free ðÞ ¼ f time   dose ðÞ þ c2 þ c2d   dose þ c20   t0
þ c21   t1 þ c22   t2 þ c2c   tc
þ c2d0   dose   t0 þ c2d1   dose   t1
þ c2d2   dose   t2 þ c2dc   dose   tc
The results for patients in the standard dose are obtained
for dose equal to zero (the ﬁxed part of the time model).
The results for patients in the high dose are obtained for
dose equal to one.
Weighting over all patterns in the pattern mixture
approach
In the pattern mixture approach, the drop-out process is
modeled by the probability to belong to a speciﬁc drop-out
pattern for each dose separately. Let p0 = (p00, p01, p02)b e
the vector of probabilities to belong to patterns 0
(deceased), 1 (relapse), or 2 (relapse free), respectively, for
patients in the standard dose. Let p1 = (p10, p11, p12)b e
the vector of probabilities to belong to patterns 0
(deceased), 1 (relapse), or 2 (relapse free), respectively, for
patients in the high dose.
The results of the pattern mixture approach are obtained
by weighting the courses over time of the different patterns
by their corresponding proportions.
So,
Yij patternmixtureapproach ðÞ ¼ p00 Yij deceased; dose¼0 ðÞ
þp10 Yij deceased; dose¼1 ðÞ
þp01 Yij relapse; dose¼0 ðÞ
þp11 Yij relapse; dose¼1 ðÞ
þp02 Yij relfree; dose¼0 ðÞ
þp12 Yij relfree; dose¼1 ðÞ :
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